Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument
The approval further strengthens the Potassium Chloride franchise for the company.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Subscribe To Our Newsletter & Stay Updated
